Case series of elderly patients with scabies topically applied with ivermectin via whole-body bathing.

ivermectin scabies scabies treatment topical treatment whole-body bathing

Journal

The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545

Informations de publication

Date de publication:
Apr 2021
Historique:
revised: 08 12 2020
received: 28 03 2020
accepted: 09 12 2020
pubmed: 8 1 2021
medline: 15 5 2021
entrez: 7 1 2021
Statut: ppublish

Résumé

As a novel method of ivermectin (IVM) administration for the treatment of scabies, we devised a whole-body bathing (WBB), in which patients are immersed in a fluid that contains IVM. A multi-institutional trial for elderly patients with scabies was conducted to investigate the efficacy and safety of IVM-WBB. Seven elderly patients with scabies were enrolled and received IVM-WBB up to four times at 1-week interval. The cure for scabies was defined as the absence of mites in two consecutive microscopic or dermoscopic examinations at weekly intervals and the absence of new skin lesions indicative of scabies. Consequently, the cure rate on day 22, the primary end-point, was 71.4%, and all patients had been cured until day 29. Additionally, neither significant adverse events nor clinically problematic abnormal blood test values were obtained. Furthermore, no IVM was detected in the optional plasma (five cases) collected for IVM measurement after bathing. These results suggest that IVM-WBB was effective to treat scabies, causing no serious adverse events and with a very low internal exposure of IVM.

Identifiants

pubmed: 33410137
doi: 10.1111/1346-8138.15746
doi:

Substances chimiques

Ivermectin 70288-86-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

559-563

Informations de copyright

© 2021 Japanese Dermatological Association.

Références

Dhana A, Yen H, Okhovat JP, Cho E, Keum NN, Khumalo NP. Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78:194-198.
WHO.net. WHO online publications. World Health Organization Model List of Essential Medicines. 21st List, 2019. [Cited 2020/03/27] Available from: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1.
Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies (Review). Cochrane Database of Sys Rev. 2018;4:1-95.
Executive Committee of Guideline for the Diagnosis and Treatment of Scabie. Guideline for the diagnosis and treatment of scabies in Japan (third edition). J Dermatol 2017; 44: 991-1014.
Miyajima A, Komoda M, Fukuzawa M, et al. Effect of high fat meal intake on the pharmacokinetic profile of ivermectin in Japanese scabies patients. J Dermatol. 2016;43:1030-1036.
Miyajima A, Komoda M, Akagi K, et al. Experimental study of pharmacokinetics of external, whole body bathing application of ivermectin. J Dermatol. 2015;42:87-89.
Miyajima A, Hirota T, Tashiro M, et al. Pharmacokinetics of ivermectin applied topically by whole-body bathing method in healthy volunteers. J Dermatol. 2017;44:406-413.
Hass N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch Dermatol. 2002;138:1618-1619.
Manjhi PK, Sinha RI, Kumar M, Sinha KI. Comparative study of efficacy of oral ivermectin versus some topical anti-scabies drugs in the treatment of scabies. J Clin Diagn Res. 2014;8:HC01-HC04.
Engelman D, Fuller LC, Steer AC. International Alliance for the Control of Scabies Delphi panel; Consensus criteria for the diagnosis of scabies: A Delphi study of international experts. PLOS Negl Trop Dis. 2018;12:1-9.
Elsner E, Uhlmann T, Krause S, Hartmann R. Increase of scabies and therapy resistance among German military personnel: An 8-year follow-up study in the Department of Dermatology of the Armed Forces Hospital. Berlin, Germany (2012-2019). Hautarzt. 2020; 71:447-454.
Thomas J, Peterson GM, Walton SF, et al. Scabies: an ancient global disease with a need for new therapies. BMC Infect Dis. 2015;15:250:1-6.

Auteurs

Masayo Komoda (M)

Department of Medical Safety, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.
Center of Translational Research, Research Institute for Science and Technology, Tokyo University of Science, Noda, Japan.

Atsushi Miyajima (A)

Department of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Department of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Machi Koshino (M)

Department of Medical Safety, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Shunta Akutsu (S)

Department of Medical Safety, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Mizuki Yamada (M)

Department of Medical Safety, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Rie Ozeki (R)

Department of Medical Safety, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.

Kuniko Makigami (K)

Tsubasa Home Care Clinic, Ohta, Japan.
Department of Rehabilitation, Ota Hospital, Higashikagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH